Can You Start an IV on the Mastectomy Side?

For decades, the blanket rule in hospitals has been simple: never start an IV, draw blood, or take blood pressure on the arm where a patient had breast cancer surgery. But the evidence behind that rule is surprisingly thin. Large prospective studies have found no significant link between ipsilateral (same-side) IV placement and the development of lymphedema, and several recent practice-change projects have allowed careful use of the surgical arm with zero resulting cases of swelling. The picture is more nuanced than either “never touch that arm” or “it’s completely fine,” and the answer depends on which surgery was performed, whether lymphedema already exists, and who is making the clinical decision.

Where the Ban Came From

The logic behind avoiding the mastectomy arm sounds reasonable on the surface. When lymph nodes under the arm are removed or damaged during breast cancer surgery, the lymphatic system on that side can’t drain fluid as efficiently. Anything that increases fluid load or introduces infection risk could theoretically tip the balance toward chronic swelling. Upper limb lymphedema is one of the most common complications after breast cancer surgery and radiation, and once it develops, it can be progressive and difficult to treat.¹

From that reasoning, hospitals built policies forbidding blood draws, IV lines, injections, and blood pressure cuffs on the affected side. The fear spread through institutional protocols, patient education materials, and breast cancer support groups until it became one of the most universally enforced precautions in oncology nursing.² The problem is that these precautions were based on theoretical risk and clinical tradition rather than actual outcome data. As one review noted, the fears have been “propagated for decades” and “have a more historical and traditional basis” rather than an evidence-based one.³

What the Largest Studies Actually Found

The strongest evidence comes from a prospective study that tracked breast cancer patients at a single institution between 2005 and 2014, measuring arm volumes before and after surgery with a device called a Perometer. At each visit, patients reported how many blood draws, injections, and blood pressure readings they’d had on the affected arm, along with flights taken and any arm trauma.⁴ This kind of long-term, real-world tracking is exactly what the field had been missing for years. The study’s design allowed researchers to look at whether specific activities on the surgical arm were actually followed by measurable swelling.

A separate large retrospective study examined nearly 8,000 IV placements in patients who had previously undergone breast cancer surgery. Out of roughly 5,150 IVs placed on the same side as the prior surgery, only two had complications, an incidence of about 4 per 10,000. The complication rate on the opposite arm was actually slightly higher at about 7 per 10,000 from roughly 2,750 IVs, and the difference was not statistically significant. Even among patients who had undergone full axillary lymph node dissection, no complications occurred when the IV was placed on the surgical side.⁵ The researchers concluded plainly that avoidance of IV placement on the breast cancer side “is not necessary.”

These findings are echoed by broader reviews. Large cohort studies have found no significant association between blood draws or IV infusion in the surgical arm and the development of lymphedema.⁶ The old recommendation to effectively eliminate vascular access on the surgical side for the patient’s entire lifetime is, in the words of that review, “neither necessary nor realistic.”

Not All Surgeries Carry the Same Lymphedema Risk

Understanding this question requires recognizing that “mastectomy side” covers a wide spectrum of surgical histories. A patient who had a lumpectomy with a sentinel lymph node biopsy, where just one or two nodes were sampled, is in a very different situation from someone who had a full axillary lymph node dissection removing ten or more nodes plus radiation to the armpit area.

A systematic review and meta-analysis covering over 9,300 patients found that the prevalence of lymphedema was about 14 percentage points higher after full axillary dissection compared to sentinel node biopsy alone.⁷ Every study in that analysis reported higher lymphedema rates after the more extensive surgery. So someone who only had a sentinel node biopsy has a meaningfully lower baseline risk of developing lymphedema at all, which makes the absolute risk of an IV triggering problems even smaller. Current thinking among researchers is that the degree of caution should be proportional to the extent of lymph node surgery, not applied as a one-size-fits-all prohibition.

A literature review reinforced this point, concluding that there is limited evidence for avoiding IV placement and blood draws in the affected arm and that best practice is to assess each patient’s individual risk factors before recommending any limb precautions.⁸ That’s a meaningful shift from “never do it” to “think about who you’re doing it to.”

The Real Harms of a Blanket Ban

What often gets overlooked in the conversation is that refusing to use the surgical arm has its own consequences. When nurses can’t access the ipsilateral arm, patients sometimes end up with blood drawn from their feet, blood pressure measured on their calves, or central venous catheters placed for routine access. Each of those alternatives carries risks that can exceed the theoretical danger of a simple arm stick.

An evidence-based practice project at one institution confronted this head-on. The old policy of blanket ipsilateral arm avoidance was leading to inaccurate calf blood pressure readings, foot-stick blood draw orders, and an increased need for tunneled central venous catheters, all of which created real complications or unreliable data. After switching to a risk-stratified approach that allowed ipsilateral arm use when appropriate, more than 100 breast cancer patients participated over 12 months with zero incidences of resulting lymphedema. There were also no foot-stick orders or calf blood pressure readings needed in patients where the ipsilateral arm was used.⁹

For patients needing chemotherapy, the question of vascular access becomes especially important. When the surgical arm is off limits and the contralateral arm has poor veins or its own limitations, clinicians often turn to central lines. A meta-analysis comparing implantable ports to peripherally inserted central catheters (PICCs) for breast cancer chemotherapy found that PICCs carried roughly 75% higher overall complication risk than implantable ports.¹⁰ These complications include bloodstream infections, thrombosis, and catheter malfunction. In other words, the device placed to “protect” the arm can itself cause serious problems.

What About Bilateral Mastectomies?

The blanket ban becomes especially absurd for patients who have had surgery on both sides. If neither arm is “allowed,” there are no peripheral options left for IV access or blood pressure monitoring. This scenario has become more common as bilateral mastectomies have increased. In practice, clinicians have to use one arm or the other, and the evidence described above suggests this is safe. But the old policy, applied rigidly, would force these patients into central lines for every hospitalization and blood draw for the rest of their lives. That outcome is clearly worse than the risk it’s trying to prevent.

Even for unilateral patients, the issue compounds over time. A breast cancer survivor might live for decades after treatment, and during those years she’ll face emergency rooms, routine surgeries, pregnancies, and chronic disease management. Telling a 40-year-old survivor she can never have an IV or blood pressure check on one arm for the next 50 years creates ongoing barriers to care that accumulate far beyond one needle stick.

When Extra Caution Still Makes Sense

None of this means that the mastectomy arm should be treated exactly like any other arm in every situation. There are scenarios where a more conservative approach is warranted.

If a patient already has established lymphedema, the calculus changes. Cellulitis, a skin infection resulting from impaired lymphatic function, is a serious complication in patients with existing breast cancer-related lymphedema and can worsen the swelling.¹¹ Any puncture of the skin introduces a potential entry point for bacteria, and a lymphedema-affected arm is already struggling to clear fluid and fight infection locally. For someone with active lymphedema, avoiding unnecessary needle sticks on that arm remains reasonable.

Several factors can help clinicians decide whether the ipsilateral arm is a safe option:

Surgical extent: Sentinel node biopsy only versus full axillary dissection makes a substantial difference in baseline lymphedema risk.
Radiation history: Axillary radiation adds to lymphatic damage and increases risk further.
Current arm status: An arm with no measurable swelling and no symptoms is different from one already showing volume changes.
Time since surgery: Lymphedema most commonly develops in the first few years after treatment, though late-onset cases do occur.
Number of nodes removed: The more nodes removed, the greater the disruption to lymphatic drainage.

The emerging consensus is that a risk-assessment approach, rather than a blanket prohibition, protects patients better. Use the surgical arm when the patient is low-risk and the clinical situation calls for it. Avoid it when established lymphedema, extensive nodal dissection, and radiation have all converged to maximize vulnerability.

What Patients Should Know and Communicate

If you’ve had breast cancer surgery, you’ll want to know the details of your own operation. Ask your surgeon how many lymph nodes were removed, whether you had a sentinel node biopsy or a full axillary dissection, and whether you received radiation to the armpit area. This information will help future healthcare providers make informed decisions rather than applying a one-size-fits-all restriction.

Many hospitals still have the old policy on their books, and many nurses have been trained to treat the mastectomy arm as untouchable. If you’re in a situation where using the surgical arm would make care easier or safer, and you’re low-risk based on your surgical history, it’s worth having a conversation with your care team rather than assuming the arm is permanently off limits. Conversely, if you have noticeable swelling, heaviness, or a history of arm infections, speak up about that too. The medical alert bracelet saying “No BP/IV Right Arm” served a purpose in an era when we had no good data, but it sometimes leads to worse care now that the evidence has shifted.

Hospital policies are changing, but slowly. Institutions that have studied the question and revised their protocols report good outcomes, as the practice-change project described earlier demonstrates.⁹ Vascular access specialists have been encouraged to develop standardized, evidence-informed guidelines for this patient population, because the current patchwork of outdated restrictions is creating problems.⁶

Newer Tools for Assessing Lymphatic Health

One reason the field is moving toward individualized risk assessment is that we now have better ways to see what’s happening in the lymphatic system. Near-infrared fluorescence imaging, using a dye called indocyanine green (ICG), allows clinicians to visualize lymphatic channels in real time under the skin. A systematic review covering over 2,000 patients found that this imaging technique could identify arm lymph nodes during axillary surgery in 80% to 88% of cases and was widely supported for diagnosing and staging lymphedema.¹²

This matters for the IV question because imaging could eventually tell a clinician whether a particular patient’s lymphatic drainage is actually compromised or has compensated well after surgery. Right now, decisions are often made based on the type of surgery alone, which is a reasonable proxy but not as precise as seeing the lymphatics directly. As these tools become more available, the shift from blanket restrictions to personalized assessment will likely accelerate. A patient whose imaging shows robust lymphatic collaterals on the surgical side could safely have routine IV access there, while a patient whose imaging reveals impaired drainage might benefit from continued caution, regardless of how long ago the surgery was.

Choosing Long-Term Vascular Access for Chemotherapy

For patients who need chemotherapy delivered over months, the vascular access decision gets more complex. The three main options are implantable chest ports, arm ports, and PICCs. A study that tailored the approach based on patient characteristics found low complication rates across all three devices, with no bloodstream infections in any group. Arm ports had a small number of thrombosis events and one elbow contracture, while PICCs saw issues like accidental removal and skin irritation. There was no statistically significant difference in thrombosis rates between PICCs and arm ports.¹³

What this suggests is that the choice of long-term access device should be individualized based on the patient’s anatomy, vein quality, treatment duration, and lifestyle, not dictated solely by which arm had surgery. When the contralateral arm has good veins and is the only option under old rules, the decision is simple. But when it doesn’t, or when central access introduces its own complications, allowing ipsilateral peripheral access when the patient is at low risk for lymphedema can spare her the downsides of a more invasive device. The broader theme is consistent: rigid rules yield to better outcomes when replaced by clinical judgment informed by the current evidence.